Who We Are

The Rationale Behind Precision Medicine

The Rationale Behind Precision Medicine


The era of one-size-fits-all medicine is giving way to treatment based on personal information that provides real evidence of whether a specific product is likely to work for a particular patient. These data may range from genetic information derived from a blood test to clinical trials leveraging novel patient stratification techniques or even consumer behavior distilled from novel big data methods.

This focus on more specific and highly comprehensive information is known as precision medicine and it is the future of healthcare delivery, with an impact on the development and commercialization of biopharmaceutical products that will be seismic. Evidence demanded by regulators and payers is increasing globally, large provider systems are reshaping themselves to bear risk, and perhaps most importantly, consumers are bearing more and more of the costs of treatment. As these trends mount, the ability to convincingly demonstrate value and validate outcomes will separate the winners and losers in the healthcare marketplace.


The ability to demonstrate value and outcomes will be fundamental…

Comprehensive Real-World Solutions

Comprehensive Real-World Solutions

At Precision Medicine Group, we deliver specialty services that help our life science clients navigate these challenges. For research and development, we bring highly specialized biomarker, laboratory, and clinical trial services as well as the regulatory expertise to manage the precision development pathway.

To address commercial excellence, we bring a uniquely specialized set of services that integrate the generation and communication of the evidence necessary to establish value, optimize access, and drive demand. These include integrated market access, advanced payer analytics, health economics, and marketing communications.

Precision Medicine Group Answers Our Clients’ Critical Business Questions



For more detailed information on the expertise and services we provide to life sciences companies, go to the Precision Medicine Group home page and explore our company websites.

  • Precision for Medicine for your research and development needs
  • Precision for Value for market access, outcomes, and commercial excellence


The Precision Medicine Group History and Founders

The Precision for Medicine Group (Precision) was founded in 2012 as Precision for Medicine by life sciences entrepreneurs Ethan Leder and Mark Clein. Leder and Clein, together with their core management team and investors, have a track record of creating, building, and managing highly successful, science-based service organizations that address next-generation product development and commercialization challenges in the life sciences industry.


Since its establishment in 2012, Precision has grown tremendously through the expansion of services and the acquisition of several companies.
In 2016, Precision entered its fifth year in business with nearly 600 employees. This talented group of individuals allows the Precision organization to support our clients in the achievement of commercial excellence through a comprehensive set of services, solutions, and expertise spanning the healthcare continuum from bench to bedside.


Our Executive Leadership

Our Executive Leadership


Ethan D. Leder

Ethan D. Leder is the Co-Founder and Executive Chairman of Precision Medicine Group. Over the past 25 years, he has been an entrepreneur focused on building and managing innovative, market-leading companies that address critical gaps in the healthcare industry. Prior to Precision Medicine Group, Leder was the Founder and CEO of United BioSource Corporation (UBC), which became the leader in real-world research addressing safety, value, and comparative effectiveness for the life science industry. UBC was acquired by Medco Health Solutions in late 2010 and is now part of Express Scripts.

Before UBC, Ethan was the Co-Founder and CEO of U.S. Bioservices, Inc., which addressed a growing need for personalized, direct-to-patient distribution of high-cost biotechnology for serious medical conditions. U.S. Bioservices was acquired by AmerisourceBergen in 2002.
Prior to U.S. Bioservices, he was the Founder and President of HealthCare Financial Partners, the leading specialty lender to the healthcare industry. It was acquired by GE Capital in late 1999.

Ethan received his undergraduate degree from Johns Hopkins University and his Juris Doctor from Georgetown University Law Center. He also serves on the Board of Trustees of Johns Hopkins University and is active in many charitable and community development projects in the Washington DC, metropolitan area.


Mark P. Clein

Mark P. Clein is the Co-Founder and CEO of Precision Medicine Group. He has over 20 years of experience in the healthcare industry. Prior to Precision, Mr. Clein was Co-Founder, President and CFO of United BioSource Corporation (UBC), which became the leader in real-world research addressing safety, value, and comparative effectiveness for the life science industry. UBC was acquired by Medco Health Solutions in late 2010 and is now part of Express Scripts.

Prior to UBC, Mr. Clein was Founder and CFO of U.S. Bioservices, a leading provider of distribution services for specialty pharmaceuticals and biologics. Mr. Clein also served as Chief Executive Officer of PMR Corporation, a leading provider of outpatient services for psychiatric and central nervous system disorders. In 2002, PMR merged with Psychiatric Solutions, Inc., which grew into the largest US provider of psychiatric inpatient services. Mr. Clein served on its board of directors until the company’s acquisition by Universal Health Systems in 2010.

He received his Master of Business Administration degree from the Columbia Graduate School of Business and his undergraduate degree from the University of North Carolina. Mr. Clein also serves on the Arts and Sciences Foundation Board at the University of North Carolina.



Chad Clark

Chad Clark is the Co-President and Chief Operating Officer at Precision Medicine Group and President of Precision for Medicine. He is a recognized industry leader focused on combining cutting-edge technology, strategic program design, and operational excellence to help life science companies effectively address the increasing evidence demands and need to accelerate research initiatives. His experience includes the execution of phase I-IV clinical trials, specialty lab services, biospecimen logistics, and banking. Additionally, he has helped clients more efficiently perform research endeavors, address critical safety issues through risk management and epidemiology programs, and support patient initiatives including reimbursement, nurse support programs, and disease management programs. His experience spans all major therapeutic areas and includes specialty products prescribed and administered in a wide variety of treatment settings.

Prior to joining Precision, he was the General Manager of Comprehensive Access and Patient Support for United BioSource Corporation (UBC). During his time there, Chad led the more than 60 Risk Evaluation and Mitigation Strategies (REMS) that UBC designed and implemented. Additionally, he developed and managed activities for some of the most complex prospective patient registries in the world, successfully launching multilingual, multinational systems and programs. Prior to UBC, he was Director of Operations at Clinical and Pharmacologic Research, Inc. (now Kendle International), a phase I/II CRO.

Chad obtained his Bachelor of Science degree in Biology from the University of North Carolina.



Dan Renick

Dan Renick, RPh, is Co-President and Chief Commercial Officer of Precision Medicine Group and President of Precision for Value. Previously, he was President of Hobart Group Holdings for 6 years prior to its acquisition by Precision Medicine Group in 2013. During his more than 20 years within the healthcare industry, Dan has accumulated a wealth of information on a wide range of industry stakeholders through a combination of direct experience, context, and insightful interpretation. Dan has worked in several key areas, including managed care, pharmaceutical managed markets, pharmacy provider operations, and market access strategic consulting.

Dan was formerly the Director of Corporate Pharmacy Management at Humana Inc. In this role, he was responsible for pharmacy programs and trade relations, including oversight of contracting with both pharmaceutical companies and pharmacy provider organizations. In addition, Dan served as the National Director of Pharmacy Networks where he worked with a variety of pharmacy channel stakeholders to improve access and quality in a cost-efficient manner.

Prior to joining Humana, Dan served as a Corporate Account Executive in the managed markets division of Merck & Co., Inc. During his tenure at Merck, Dan worked with large employers, business coalitions, and benefits consultants in support of rational and evidence-based benefit design decisions. In addition, he worked with various other managed markets segments with an emphasis on the senior care market.

Dan received his pharmacy degree from the University of Kentucky and his bachelor of science degree in chemistry and biology from Western Kentucky University.

Areas of Expertise

  • Managed care, pharmaceutical managed markets, pharmacy provider operations, and market access strategic consulting
  • Managed markets segments, including the senior care marketplace and employer groups